Glutamate is the brain’s main excitatory messenger. Esketamine blocks one of its receptors and can ease depression within hours. Blocking excitement to treat depression sounds backward, until you see what that receptor actually does.
Part 5 of the Brain Chemistry series. New here? Start with Your Brain Is Not a Gas Tank, the short orientation that explains the four questions every article in this series answers.
What to know
- Glutamate is the brain’s main fast excitatory messenger. It supports learning and memory, but more excitation is not automatically better, and blocking a glutamate receptor is not automatically calming.
- Esketamine (Spravato) and ketamine both block the NMDA receptor, a specific glutamate receptor gate. That receptor blockade is fast. The antidepressant benefit that can follow is not fully explained by any single downstream step.
- Spravato carries a boxed warning and requires monitored dosing under an active federal safety program. Its label states plainly that it has not been shown to prevent suicide or reduce suicidal thoughts and behavior.
- Ketamine’s label warns about liver and bile-duct injury with recurrent use, and about profound sedation, dangerously slowed breathing, coma, or death when combined with opioids, benzodiazepines, or alcohol.
- Two other drugs designed to boost NMDA signaling through a different route, bitopertin and iclepertin, engaged their intended target in testing and still failed to show meaningful clinical benefit. Hitting a target and helping a patient are two different accomplishments.
The short answer
Glutamate is the brain’s main fast excitatory amino-acid messenger. It activates several kinds of receptors, including one called NMDA, which behaves unlike most others in the brain. An NMDA receptor will not open from glutamate alone. It also needs a second helper molecule, usually glycine, sitting in a separate slot, plus the right electrical state in the surrounding cell membrane. All of these conditions have to line up together before the channel opens.
Glycine itself has two separate jobs. In the spinal cord and lower brain, it usually calms cells down, acting as its own inhibitory signal. In the forebrain, at NMDA receptors specifically, it instead serves as the helper molecule that allows the excitatory channel to open. The same chemical is a brake in one location and a required part of the “go” signal in another.
Esketamine, ketamine, dextromethorphan, and memantine all directly block the NMDA channel, but they do it in different ways, at different exposures, and for different approved uses. A fast receptor block is the first step of a slower chain of events involving other receptors and long-term changes in brain connections. More glutamate signaling is not automatically better, and less is not automatically safer.
Fast excitation. A receptor called AMPA carries most of the brain’s routine, rapid excitatory signaling between cells. NMDA receptors add something slower and more selective on top of that: signaling that depends on the cell’s recent activity, not just whether glutamate is present.
Learning and memory. NMDA-driven calcium entry, together with changes in how AMPA receptors are positioned at a synapse, supports several forms of learning-related brain change. Too little activation and too much activation can both disrupt this process. A stronger signal is not automatically a better memory.
Mood treatment. This is where the puzzle lives. Clinical trials show that NMDA-blocking drugs can help specific groups of patients with depression, sometimes quickly. Researchers still debate the exact sequence of steps that connects blocking this receptor to feeling better.
Psychosis research. Models where NMDA receptors work less than normal can reproduce some features of psychosis and thinking difficulties in research settings. This does not establish that everyone with schizophrenia has the same NMDA problem.
Severe brain injury. During a stroke or another major energy crisis in brain tissue, the normal systems that clear glutamate away can fail, and excessive receptor activation can contribute to cell injury.1 This process, called excitotoxicity, describes a medical emergency. It is not a description of ordinary anxiety, depression, or feeling overstimulated.
Meet the glutamate targets
| Receptor or target | What it does, where it matters, and why you might care |
|---|---|
| AMPA receptor | What it does: A fast channel that carries most routine excitatory signaling. Where it matters: Widely distributed across the cortex, hippocampus, and other pathways. Why you might care: Carries most day-to-day excitation. Later AMPA-related changes are part of leading theories of how ketamine-family medicines produce lasting benefit. |
| NMDA receptor | What it does: A channel that needs glutamate, a helper molecule, and the right electrical state together before it opens. Where it matters: Found across the brain, especially where learning-related change happens. Why you might care: The direct target of esketamine, ketamine, dextromethorphan, and memantine. |
| Group I metabotropic receptors | What it does: A slower signal that typically increases how excitable a cell is. Where it matters: Postsynaptic sites in various circuits. Why you might care: An active area of research; no routine psychiatric treatment currently targets these on purpose. |
| Glycine receptor | What it does: A channel that typically calms a cell down. Where it matters: Spinal cord, brainstem, and some brain sites. Why you might care: Shows why glycine is not only an NMDA helper molecule. This separate, inhibitory glycine receptor is what the poison strychnine blocks. |
| GlyT1 transporter | What it does: Controls how much glycine is available near NMDA receptors. Where it matters: Glial and neuronal sites in the forebrain. Why you might care: A promising-looking schizophrenia target that did not translate into a working medicine, discussed below. |
Where the science still argues
Scientists agree that ketamine and esketamine directly block NMDA receptors. They do not agree on the one complete sequence that connects that blockade to feeling better. Competing explanations point to changes in inhibitory GABA cells, later effects on AMPA signaling, specific breakdown products of the drug itself, and lasting changes in the strength of brain connections. More than one of these may matter, and the field has not settled which steps are truly necessary.
The GlyT1 story is one of the clearest lessons in this whole field about the gap between hitting a target and helping a patient. GlyT1 controls glycine near NMDA receptors, and blocking it should, in theory, make it easier for NMDA receptors to open. Bitopertin was built on exactly that logic and engaged its target in testing. Its phase 3 trials did not show the hoped-for improvement in schizophrenia’s persistent negative symptoms.12 A second drug, iclepertin, was tested for a different goal, cognitive improvement in schizophrenia, across three linked phase 3 trials. None of the three showed a significant benefit.13 Neither failure erases the underlying biology. It shows that a correct receptor idea does not automatically become a working medicine, because the target may not actually drive the symptom, the brain circuit may compensate, or the patients selected for the trial may not share the relevant biology.
Can glutamate signaling be measured?
Only through narrow research tools, none of which answer an individual clinical question.
Magnetic resonance spectroscopy, or MRS, can estimate glutamate-related chemical activity inside a defined region of the brain. One human study found a measurable, acute change in this signal after a dose of ketamine, but that was a research finding in a controlled experiment, not a diagnostic test, and it did not prove that the measured change was what caused the person to feel better.2
A specialized scan can measure how much of a particular receptor a drug is occupying, when a suitable tracer is available. That tells researchers the drug reached and bound its target under the conditions studied. It does not tell you whether that binding produced a benefit. Blood, spinal fluid, urine, and other body fluids reflect diet, metabolism, and other bodily processes far more than they reflect signaling inside a relevant brain circuit. No routine test can report your glutamate signaling in a way a prescriber can act on.
What each medicine actually touches
| Medicine | What it does directly, used for, and main tradeoffs |
|---|---|
| Esketamine nasal spray (Spravato) | What it does directly: Blocks the NMDA receptor channel. Used for: Specific adult depression indications, given under a monitored program. Main tradeoffs: Boxed warning for sedation, dissociation, dangerously slowed breathing, misuse, and suicidal thoughts and behaviors. Requires supervised in-clinic dosing under an active federal safety program. The label states plainly that it has not been shown to prevent suicide or reduce suicidal thoughts or behavior. |
| Ketamine | What it does directly: Blocks the NMDA receptor channel; forms active breakdown products in the body. Used for: An approved anesthetic; depression treatment is off-label and depends heavily on the setting. Main tradeoffs: Dissociation and cardiovascular effects. The label warns that recurrent use, including medically supervised off-label use, is linked to liver and bile-duct injury. Combining it with opioids, benzodiazepines, or alcohol can cause profound sedation, dangerously slowed breathing, coma, or death. |
| Dextromethorphan-bupropion (Auvelity) | What it does directly: Dextromethorphan blocks NMDA receptors; bupropion slows how quickly the body clears dextromethorphan, extending its exposure. Used for: Major depression in adults, and, as of 2026, agitation linked to Alzheimer’s-related dementia in adults. Main tradeoffs: Boxed antidepressant suicidality warning, seizure risk, and blood pressure increases. |
| Memantine | What it does directly: Blocks the NMDA receptor channel in a voltage-dependent way. Used for: Moderate to severe Alzheimer’s-type dementia. Main tradeoffs: Dizziness, headache, and interactions tied to kidney function and urine acidity. |
| Bitopertin and iclepertin | What it does directly: Block the GlyT1 transporter to raise glycine availability near NMDA receptors. Used for: Studied for schizophrenia symptoms; not FDA approved. Main tradeoffs: Neither established meaningful clinical benefit in phase 3 testing, despite engaging their intended target as designed. |
The current Spravato label confirms its Schedule III status, its active safety monitoring program, and its boxed warning, and it sets a boundary worth repeating: the medicine has not been shown to prevent suicide or to reduce suicidal thoughts or behavior.6 Feeling better after a dose does not rule out the need for a higher level of care.
Why benefit and side effects come from the same system
Follow esketamine through the system: it blocks NMDA receptor channel sites during certain patterns of activity. That first step changes both excitatory and inhibitory signaling in the surrounding network. It can cause dissociation, sedation, or a rise in blood pressure in the short term. Over a longer time, changes in synaptic connections may contribute to easing depression.
The immediate, felt effects are not a preview of whether benefit is coming. A person can feel strong dissociation during a dose and see no lasting improvement. Another person can improve meaningfully without much dissociation at all. Two NMDA-blocking medicines can feel very different from each other, because their timing, route into the body, breakdown products, and other targets all differ. Memantine’s role in dementia care does not make it interchangeable with ketamine’s role in depression.
What people may notice over time
The molecular target can be engaged within minutes to hours. Clinical benefit, if it happens, can follow on its own, different timeline, because the brain networks involved need time to process the change and adapt. There is no single schedule that applies to everyone.
Early effects of these medicines can include dizziness, nausea, sleepiness, dissociation, unusual sensory experiences, or blood pressure changes, depending on the specific drug. Repeated exposure can lead to tolerance for some effects. Never use a general timeline from this article to change a dose or stop a medicine on your own. The specific product, dose, and your individual health history all matter.
Which symptoms need a call, and which need urgent help
Track and mention at your next visit: mild, expected effects you have already reviewed with your prescriber, such as brief nausea or dizziness, as long as they stay mild and improve.
Call the prescriber or pharmacist promptly: troubling sedation, repeated vomiting, worsening confusion, new agitation, new manic symptoms, or a significant blood pressure concern. Do not drive or do anything hazardous when a label or your clinician has warned about impairment.
Contact Poison Control at 1-800-222-1222 for a suspected overdose, an accidental double dose, or a dangerous combination with another substance.
Call 911 now for a seizure, loss of consciousness, severe breathing difficulty, chest pain, signs of stroke, or extreme confusion paired with unsafe behavior. Do not wait for a routine callback from your prescriber’s office. For a suicidal or mental health crisis, call or text 988. If danger is immediate, call 911.
D-cycloserine deserves a specific mention, even though it is not a routine psychiatric medicine. Its current antibacterial label lists epilepsy, depression, severe anxiety, psychosis, severe kidney impairment, and excessive alcohol use among its contraindications.14 Depression of any severity is on that list, not only severe depression. That label’s caution is one clear reason a promising receptor idea should never become a self-treatment plan.
What to ask your prescriber
These are conversation starters, not instructions.
- Which symptom or functional problem is this medicine meant to target?
- Which receptor site does it bind directly, and which effects come later, downstream?
- What improvement should we look for first, and by when?
- Does this product require monitored, in-clinic administration or a safety program?
- What interactions matter, especially with alcohol, sedatives, or other central nervous system depressants?
- Could sudden stopping cause discontinuation symptoms, or a return of the underlying illness?
- If ketamine is being used off-label for depression, how will liver function be monitored over time?
- Has this medicine actually been shown to reduce suicidal thoughts, or only to treat the labeled depressive symptoms?
Bottom line
A response to esketamine or ketamine does not prove your glutamate was too high before treatment. As Why Two Opposite Medicines Both Target Dopamine shows for dopamine, and What Benzodiazepines Actually Do to the Brain’s Brakes shows for GABA, this pattern repeats across brain chemistry: a fast molecular action, and a slower, larger story about what actually helps a person feel better. See Your Brain Is Not a Gas Tank for why “levels” thinking falls short here too.
Glutamate and its NMDA receptor sit at the center of learning, memory, and mood treatment, but blocking that receptor is a specific, defined action, not a blunt dial. The GlyT1 story is worth remembering any time a new “promising target” makes headlines: reaching a target correctly, as bitopertin and iclepertin both did, is not the same as helping the people who need it.
Frequently asked questions
Does depression mean my glutamate is high or low?
No. Depression is diagnosed from symptoms, duration, and impairment, not a glutamate measurement. A response to an NMDA-active medicine does not reveal what originally caused the depression.
If esketamine blocks NMDA receptors quickly, why can benefit take longer?
Blocking the receptor is only the first step. Changes in network activity, other receptor systems, and synaptic connections may unfold over a longer period, and researchers still debate exactly which of these steps are necessary for benefit.
Are ketamine and memantine basically the same medicine?
No. Both block NMDA channels, but their timing, route into the body, approved uses, and safety profiles are all different. Memantine treats dementia.9 Ketamine’s use in depression is off-label and comes with its own distinct warnings.7
Does feeling dissociated during a dose mean esketamine is working?
No. Dissociation is a known side effect, not a validated sign that benefit is coming. A person can feel strongly dissociated and see no lasting improvement, or improve without much dissociation at all.
Why did GlyT1 drugs fail if GlyT1 is a real, valid target?
A drug can hit its intended target precisely and still not help. The target may not actually be what drives the symptoms, the brain circuit may find a way to compensate, or the patients in the trial may not share the exact biology the drug was designed for. Bitopertin and iclepertin both illustrate this.1213
Is ketamine safe to use repeatedly for depression?
The label carries a specific warning that recurrent use, including medically supervised off-label use, has been linked to liver and bile-duct injury.7 This is a real, drug-specific risk that needs monitoring, not an argument to avoid discussing ketamine with a prescriber.
Related reading on NP FADY
- Your Brain Is Not a Gas Tank (start here)
- What Benzodiazepines Actually Do to the Brain’s Brakes
- IV Ketamine for Depression: What the Infusions Do and What the Trials Show
- Spravato (Esketamine) for Depression: Who It Is For and What a Visit Is Like
References
1. Foundational review of the glutamate-glutamine cycle and excitotoxicity. PMC. Accessed August 31, 2026. https://pmc.ncbi.nlm.nih.gov/articles/PMC4133642/
2. Human spectroscopy study of prefrontal glutamate-glutamine cycling after ketamine. PMC. Accessed August 31, 2026. https://pmc.ncbi.nlm.nih.gov/articles/PMC6098048/
3. IUPHAR ionotropic glutamate receptor family record. Accessed August 31, 2026. https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=75
4. Glycine-site NMDA strategies review. PMC. Accessed August 31, 2026. https://pmc.ncbi.nlm.nih.gov/articles/PMC8517243/
5. Ketamine-metabolite review. PMID: 34968492
6. Esketamine (Spravato) prescribing information. DailyMed. Accessed August 31, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?audience=consumer&setid=d81a6a79-a74a-44b7-822c-0dfa3036eaed
7. Ketamine injection prescribing information. DailyMed. Accessed August 31, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=58c86d9b-8694-4bd8-8254-f19ee3ad60b0
8. Ketamine (KETALAR) NDA approval letter. FDA. Accessed August 31, 2026. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/016812Orig1s046ltr.pdf
9. Memantine oral solution prescribing information. DailyMed. Accessed August 31, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=421f6478-09df-49d3-a7c4-52814b4aa90e
10. Dextromethorphan-bupropion (Auvelity) prescribing information. DailyMed. Accessed August 31, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dcefda7c-9a68-278e-e053-2995a90aec79
11. FDA press announcement, Auvelity agitation-in-dementia indication approval. 2026. Accessed August 31, 2026. https://www.fda.gov/news-events/press-announcements/fda-approves-first-non-antipsychotic-drug-treat-agitation-associated-dementia
12. Bitopertin phase 3 report. PMID: 28117049
13. Iclepertin CONNEX phase 3 report. PMID: 41233083
14. D-cycloserine prescribing information. DailyMed. Accessed August 31, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10727aa8-a03e-4b61-9a80-a024cb4a2d28
This article is general education. It is not a diagnosis or a treatment plan. Do not start, stop, or change a medicine because of something you read here. Review every prescription, supplement, and substance with your prescriber or pharmacist.
If you or someone you know is in crisis
- Call 911 or go to your nearest emergency room for any life-threatening emergency.
- 988 Suicide & Crisis Lifeline — call or text 988, available 24/7. En español: marque 988 y oprima 2. Veterans: 988 and press 1, or text 838255.
- Crisis Text Line — text HOME to 741741.
- The Trevor Project (crisis support for LGBTQ+ young people) — call 1-866-488-7386, or text START to 678-678.
- National Sexual Assault Hotline (RAINN) — call 1-800-656-HOPE (4673) or text HOPE to 64673; free, confidential, 24/7. Online chat at RAINN.org/hotline.
- National Domestic Violence Hotline — call 1-800-799-SAFE (7233) or text START to 88788; 24/7, help in 200+ languages. Online chat at TheHotline.org. If your phone or computer may be monitored, calling from a safer device is an option.
- Riverside County — Inland SoCal Crisis Helpline 951-686-HELP (4357), 24/7 (Inland SoCal United Way / 211+, in partnership with RUHS-BH); Community Access, Referral, Evaluation and Support (CARES) Line 800-499-3008, 24/7.
- San Bernardino County — Access Unit (Behavioral Health Helpline) 888-743-1478, 24/7; Mobile Crisis/CCRT 800-398-0018 (24/7, all ages) or text 909-420-0560. Arrowhead Regional Medical Center (ARMC) has a dedicated walk-in adolescent psychiatric ER (ages 13–17).
- Children under 13 — call 911 for immediate danger, contact your county's mobile crisis team (they respond to all ages), or go to the nearest pediatric emergency room.
- California Peer-Run Warm Line (non-crisis — someone to talk to) — call or text 1-855-600-WARM (9276); daytime and evening hours, not a 24/7 line.
- NP Fady (non-emergency) — for routine scheduling or questions, call (909) 707-6261. This line is not monitored for emergencies.